Opportunity Analysis of H1N1 (swine flu) Vaccination Market

Opportunity Analysis of H1N1 (swine flu) Vaccination Market

Report Description

H1N1 Influenza A (2009) is the first pandemic influenza of 21st century affecting more than more than four lac people in more than 180 countries across the globe in 2009. The flu broke in Mexico in the month of March and then affected U.S. and after that it spread across the globe. H1N1 (2009) influenza have a mutation of pig, bird and humans which has made it more dangerous and fatal compared to previous occurrence of H1N1 (1918).

The pandemic outbreak of the influenza opened the gates for the drugs such as Tamiflu in the initial phase for the curing of the disease but the following phase will see a shift from curing to prevention. Thus, arise the requirement for the vaccine for the treatment of H1N1. H1N1 vaccine market is the forecast for the upcoming vaccines for the prevention of the disease among the unaffected population. The vaccines market is classified for the intramuscular vaccines and intranasal vaccines. Intramuscular will cater 80-85% of market revenues and the remaining will be tapped by the intranasal vaccines. The initial lot of vaccines will be of egg based and cell based manufacturing. The market forecast is from late 2009 as the first lot of doses are expected to be rolled out in the first week of October 2009.

The first movers of the in the vaccines market are Glaxo Smith Kline (GSK), Novartis, CSL, Medimmune, Baxter, Sinovec and Sanofi Pastuer. Medimmune is the only producer of the intranasal vaccine whereas other companies are expected to come out with intramuscular vaccines. The companies have got approvals for their first lots from the governments of the various countries such as U.S., U.K., France, China, Denmark and Australia. The involvement of government bodies, increased awareness about prevention and pandemic situation of the influenza is driving the market for the vaccines.

Due to intensive ongoing research and technology introduction, the market players are compelled to understand the market dynamics, innovations, pricing, products, marketing and regulatory framework of the market.

The global H1N1 Influenza vaccine market is estimated to be of 676 million in 2009 with first lot of doses being commercialized on 30th September’ 2009. The market will see a high CAGR for the next two years i.e. the market is expected to be at $7.03 billion in 2011 with a CAGR of 222.4% from 2009 to 2011. However, the very high CAGR will settle down by 2012 to 30% for the period of 2009 to 2012. The reason for the sudden settle down of the growth is that it is expected that most of the world population will be immunized by the end of 2011.

Market estimates and forecast

This report will enable strategic understanding and opportunities in the H1N1 2009 influenza vaccines market. The report covers the following market segments.

Vaccines Markets:
Intramuscular Vaccines and Intranasal vaccines.

Geography Markets:
North America, Europe, Asia-Pacific and ROW

Each section of the report offers market data with respect to segments and geography. It also provides market trends with respect to drivers, restraints and opportunities. The report contains strategic section with respect to competitive landscape and market overview. The report will encompass around 15 company profiles

What makes our reports unique?

- We provide the longest market segmentation chain in this industry- not many reports provide market breakdown upto level 5.
- We provide 10% customization. Normally it is seen that clients do not find specific market intelligence that they are looking for. Our customization will ensure that you necessarily get the market intelligence you are looking for and we get a loyal customer.
- We conduct detailed market positioning, product positioning and competitive positioning. Entry strategies, gaps and opportunities are identified for all the stakeholders.
- Comprehensive market analysis for the following sectors:
Pharmaceuticals, Medical Devices, Biotechnology, Semiconductor and Electronics, Energy and Power Supplies, Food and Beverages, Chemicals, Advanced Materials, Industrial Automation, and Telecom and IT. We also analyze retailers and super-retailers, technology providers, and research and development (R&D) companies.

Key questions answered

- Which are the high-growth segments/cash cows and how is the market segmented in terms of applications, products, services, ingredients, technologies, and stakeholders?
- What are market estimates and forecasts; which markets are doing well and which are not?
- Where are the gaps and opportunities; what is driving the market?
- Which are the key playing fields? Which are the winning edge imperatives?
- How is the competitive outlook; who are the main players in each of the segments; what are the key selling products; what are their strategic directives, operational strengths and product pipelines? Who is doing what?

Powerful Research and analysis

The analysts working come from renowned publishers and market research firms, globally, adding their expertise and domain understanding. We get the facts from over 22,000 news and information sources, a huge database of key industry participants and draw on our relationships with more than 900 market research companies across the world. We are inspired to help our clients grow by providing qualitative business insights with our huge market intelligence repository.

Table of contents


1. Introduction
1.1. Key Take-Aways
1.2. Report Description
1.3. SCOPE AND FORMAT
1.4. STAKEHOLDERS
2. Summary
2.1. Research Methodology
3. Market Overview
3.1. 1918 Spanish Influenza (H1N1) Pandemic
3.1.1. 1957 – Asian Flu (H2N2)
3.1.2. 1968 – HongKong Flu
3.2. 2009 H1N1 Influenza
3.2.1. H1N1 pandemic cycle
4. Market Dynamics
4.1. Drivers & Restraints
4.1.1. Cost of vaccines
4.1.2. Vaccine Awareness
4.1.3. Side-effects of vaccines
4.1.4. Type of vaccine & availability of substitute treatment
4.2. market forces analysis
4.2.1. Supply-Side Drivers
4.2.2. Demand-Side Drivers
4.2.3. Restraints & Opportunities
4.3. Pricing of H1N1 vaccines
4.4. Consumer insights
5. Global H1N1 2009 Influenza vaccine Market
5.1. Market Overview
5.1.1. Priority Groups for the H1N1 vaccines
5.2. Drivers & Restraints
5.2.1. Public-private partnerships for supply of H1N1 vaccines
5.2.2. Government subsidies for vaccine manufacture
5.2.3. Revenue-increasing source
5.2.4. High costs & lengthy manufacturing process
5.3. Opportunities
5.3.1. Shift from egg-based to cell-based manufacturing
5.3.2. Market for Adjuvants
5.3.3. Opportunity for emerging economies
5.4. Manufacturing Process of Influenza Vaccines
5.4.1. Egg-based Manufacturing
5.4.2. Cell-based Manufacturing
5.4.3. Recombinant Technology
5.5. Intramuscular H1N1 Vaccine Market
5.5.1. Drivers & Restraints
5.5.1.1. Caters to large population segment
5.5.1.2. Rates low on user-friendliness
5.6. Intranasal H1N1 Vaccine
5.6.1. Drivers & Restraints
5.6.1.1. User-friendly administration
5.6.1.2. Fewer side-effects & improved efficacy
5.6.1.3. Insurance coverage
5.6.1.4. Limited consumer segment
5.6.2. Competitive Analysis
5.7. Benchmarking of Approved VACCINES
5.7.1. Pipeline overview of H1N1 vaccines
6. Geographical analysis of Global H1N1 vaccines Market
6.1. Moon Matrix analysis of global 2009 H1N1 influenza vaccine, by geography
6.1.1. Healthcare Expenditure & government contracts
6.1.2. spread of H1N1 & availability of H1N1 vaccines
6.2. North American H1N1 Vaccine market
6.2.1. Drivers & Restraints
6.3. Europe H1N1 Vaccine Market
6.3.1. Drivers & Restraints
6.4. Asia Pacific H1N1 Vaccine Market
6.4.1. AUSTRALIA
6.4.2. CHINA
6.4.3. JAPAN
6.4.4. INDIA
6.5. Rest Of World (ROW) H1N1 vaccine market
7. Strategic Conclusion
8. Company Profiles
8.1. Baxter International Inc
8.2. Butantan Institute
8.3. Cantacuzino Institute of Sera and Vaccines
8.4. Changchun Institute of Biological Products
8.5. Crucell N.V.
8.6. CSL
8.7. Denka Seiken Co. Ltd
8.8. Green Cross Corp
8.9. GlaxoSmithKline Plc
8.10. Hualan Biological Engineering Inc
8.11. Inovio Biomedical Corp
8.12. Kitasato Institute
8.13. MedImmune
8.14. Merck & Co
8.15. Novartis
8.16. Novavax
8.17. Omninvest
8.18. PANACEA BIOTEC
8.19. Sanofi-Pasteur
8.20. Shanghai Institute of Biological Products
8.21. Sinovac Biotech Ltd
8.22. SERUM INSTITUTE OF INDIA LTD
8.23. Solvay
8.24. Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd

LIST OF TABLES

SUMMARY TABLE GLOBAL MARKET FOR 2009 H1N1 INFLUENZA VACCINE, BY PRODUCTS 2009 – 2011 ($MILLIONS)

TABLE 1WHO-DEFINED LEVELS OF PANDEMIC INFLUENZA
TABLE 2GLOBAL H1N1 2009 INFLUENZA VACCINE MARKET, BY PRODUCTS 2009 – 2011 ($MILLIONS)
TABLE 3GLOBAL H1N1 INFLUENZA VACCINE MARKET, BY GEOGRAPHY 2009 – 2011 ($MILLIONS)
TABLE 4GLOBAL MARKET FOR INTRAMUSCULAR H1N1 VACCINES, BY GEOGRAPHY 2009 – 2011 ($MILLIONS)
TABLE 6GOVERNMENT INTIATIVES FOR H1N1 VACCINES
TABLE 7CONTRACTS FOR H1N1 VACCINES
TABLE 8MARKET DEVELOPMENTS FOR H1N1 VACCINES
TABLE 5BENCHMARKING OF VACCINES
TABLE 9PRODUCTION SCENARIO OF VACCINES
TABLE 10 H1N1 VACCINE TRIALS
TABLE 11 NORTH AMERICAN MARKET FOR H1N1 INFLUENZA VACCINE, 2009 – 2011 ($MILLIONS)
TABLE 12 ASIA PACIFIC MARKET FOR H1N1 VACCINE, 2009- 2011 $MILLIONS)

LIST OF FIGURES

FIGURE 1 PANDEMIC WAVE DIAGRAM – SPANISH INFLUENZA
FIGURE 2 SPANISH FLU FATALITIES IN THE U.S. (1918-1919)
FIGURE 3 PANDEMIC SCENARIO OF HONG KONG FLU
FIGURE 4 PANDEMIC INFLUENZA CYCLE
FIGURE 5 H1N1 2009 INFLUENZA VACCINE MARKET DYNAMICS
FIGURE 6 TIER PRICING MODEL FOR H1N1 VACCINES
FIGURE 7 CONSUMER PERSPECTIVE FOR H1N1 VACCINE MARKET
FIGURE 8 PRODUCT LIFECYCLE IN H1N1 VACCINE MARKET
FIGURE 9 RECOMMENDED PRIORITY GROUPS FOR 2009 H1N1 INFLUENZA VACCINES
FIGURE 10 TIMELINE OF COMMERCIALIZATION OF VACCINES
FIGURE 11 CONTRACT SHARING OF COMPANIES (2009)
FIGURE 12 GLOBAL SCENARIO OF PANDEMIC INFLUENZA
FIGURE 13 GLOBAL H1N1 INFLUENZA VACCINE MARKET, BY GEOGRAPHY
FIGURE 14 MOON MATRIX OF H1N1 VACCINE MARKET, BY GEOGRAPHY